BiomX Inc.

Good morning and welcome to the Biomix first quarter 2022 financial results and corporate update conference call. Currently, all participants are in a listen-only mode. There will be a question and answer session at the end of this call. I would now like to turn the call over to Marina Wilson, Chief Financial Officer of Biomix. Please proceed.

Thank you and welcome to the Biomix first quarter 2022 financial results and corporate update conference call. The news release became available just after 6.30 a.m. Eastern Time today and can be found on our website at biomics.com. A replay of this call will be available on the Investors section of our website. Before we begin, I'd like to review the Safe Harbor provision. All statements on this call that are not factual historic statements may be deemed forward-looking statements. For instance, we're using forward-looking statements when we discuss on the conference call potential market opportunities, the design, aim, expected timing, interim and final results of our preclinical and clinical trials, the sufficiency of our existing cash, cash equivalents, and short-term deposits, our capitalization, the potential receipt of additional cash if milestones are met, the potential benefits of our product candidates, and potential growth in shareholder value. Except as required by law, we did not undertake to update forward-looking statements. The full Safe Harbor provision, including risks that could cause actual results to differ from these forward-looking statements, are outlined in today's press release, which, as noted earlier, is on our website. Joining me on the call this morning is Jonathan Sellerman, Chief Executive Officer of Biomics. With that, I will turn the call over to Jonathan.

Thank you, Marina, and good morning, everyone. Having recently released our 2021 annual report, our first quarter update will have limited new information over what we reported just a few weeks ago on our fourth quarter conference. So I intend to keep the remarks brief on this call and reserve more time for the question and answer session. I'd like first to provide an update on BX004, which is being developed for the treatment of chronic respiratory infections in patients with cystic fibrosis, or CF. At present, we are working actively to enroll patients in the Phase 1b-2a trial, and we continue to expect initial data from the Phase 1b portion of the trial in the third quarter of 2022. As noted in our prior update, our CEA program is being supported through a therapeutic development award from the Cystic Fibrosis Foundation, an organization that has been instrumental in supporting the development of so many life-saving medicines for cystic fibrosis patients. We are also very excited to announce that tomorrow, May 12th, BioNIC will host a KOL webinar to discuss the treatment landscape for CF patients with chronic lung infections and the potential of BX004 to address patients with chronic pseudomonas aeruginosa infections. The first part of the event will feature prominent CF clinicians who will review the current treatment modalities and the unmet medical need in treating cystic fibrosis patients with chronic pseudomonas aeruginosa infections. Following the KOL presentations, Biomics will present its phage therapy, BX004, as a potential treatment solution providing a review of phage candidates' preclinical activity and an overview of the ongoing clinical development plan. Let me now briefly turn to BX005 program, which is being developed for the treatment of atopic dermatitis. I am happy to report that in April 2022, the FDA cleared the IND application for atopic dermatitis candidate BX005. BX005 has been designed to restore the skin microbiome composition of AB patients back to its pre-flare state by reducing staphylococcus aureus burden, a bacteria associated with exacerbating inflammation in this particular skin condition. We anticipate initial data from our Phase I-II proof-of-concept trial in the fourth quarter of 2022. I'd now like to turn the call over to Marina Wolfson, our Chief Financial Officer, to cover our financial results for the first quarter.